vimarsana.com

Page 2 - சீனா தேசிய மருந்து குழு இணை லிமிடெட் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Sinopharm COVID-19 vaccines: What the latest study shows

Sinopharm to inject Rs 4 6 billion vaccine assets into unit Tiantan Biological

Sinopharm to inject Rs 4.6 billion vaccine assets into unit Tiantan Biological SECTIONS Last Updated: Apr 16, 2021, 11:07 AM IST Share Synopsis Sinopharm aims to begin the injection of six vaccine-focused biological products developers including makers of two COVID-19 vaccines into Shanghai-listed Tiantan in the coming weeks, said the people plus two other people with knowledge of the matter. Reuters Chinese state-owned Sinopharm plans to inject 30 billion yuan ($4.6 billion) in assets into unit Beijing Tiantan Biological Products Corp Ltd to quickly get its fast-growing vaccine business on the public market, two people told Reuters. Sinopharm aims to begin the injection of six vaccine-focused biological products developers including makers of two COVID-19 vaccines into Shanghai-listed Tiantan in the coming weeks, said the people plus two other people with knowledge of the matter.

Exclusive: Sinopharm to inject $4 6 billion vaccine assets into unit Tiantan Biological – sources

By Syndicated Content By Julie Zhu HONG KONG (Reuters) - Chinese state-owned Sinopharm plans to inject 30 billion yuan ($4.6 billion) in assets into unit Beijing Tiantan Biological Products Corp Ltd to quickly get its fast-growing vaccine business on the public market, two people told Reuters. Sinopharm aims to begin the injection of six vaccine-focused biological products developers including makers of two COVID-19 vaccines into Shanghai-listed Tiantan in the coming weeks, said the people plus two other people with knowledge of the matter. The plan comes as China races to develop more homegrown COVID-19 vaccines to challenge Western rivals. President Xi Jinping has pledged China s vaccines for the global public good.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.